Trial Profile
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs AP-30663 (Primary)
- Indications Atrial fibrillation
- Focus Proof of concept; Therapeutic Use
- Sponsors Acesion Pharma
- 01 Jan 2024 Status has been changed to discontinued, as per Results published in the Nature Medicine
- 01 Jan 2024 Results published in the Nature Medicine
- 13 Dec 2023 According to Acesion Pharma media release full data from the study were presented in Nature Medicine